Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

128 trials

NCT07578077
Recruiting
Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 1/2 · United States · 1 site
Registry update: 22 Oct 2026
NCT07892027
Recruiting
Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy
Phase 2 · United States · 1 site
Registry update: 23 Oct 2026
NCT06675123
Recruiting
Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 1 · United States · 1 site
Registry update: 14 Oct 2026
NCT07763210
Recruiting
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
Phase 2 · United States · 1 site
Registry update: 2 Oct 2026
NCT07225439
Recruiting
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Phase 1 · United States · 2 sites
Registry update: 9 Sept 2026
NCT07788118
Recruiting
A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
Phase 1/2 · China · 1 site
Registry update: 26 Aug 2026
NCT07341191
Recruiting
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
Phase 2 · Canada · 5 sites
Registry update: 14 Oct 2026
NCT07673367
Recruiting
Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma
Phase 2 · United States · 1 site
Registry update: 17 Aug 2026
NCT07719556
Recruiting
Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)
Phase 2 · China · 2 sites
Registry update: 22 Jul 2026
NCT07609862
Recruiting
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Phase 1/2 · China · 1 site
Registry update: 30 Jul 2026
NCT07003295
Recruiting
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Phase 2 · United States · 11 sites
Registry update: 2 Nov 2026
NCT07691606
Recruiting
A Study of ARC-02 in B-cell NHL
Phase 1 · Australia, Spain, France, Italy, Poland, United States · 28 sites
Registry update: 2 Nov 2026
2025-521666-10-01
Recruiting
PirtobrUtinib as frontline Therapy for elderly unfit/frail patient with MAntle cell lymphoma: a phase II study of the Fondazione Italiana Linfomi (FIL)
Phase 2 · Italy · 20 sites
Registry update: 30 Apr 2026
2025-523428-39-00
Recruiting
Study carried out at multiple centers to test Glofitamab in patients with mantle cell lymphoma who did not respond well to, or relapsed after, CAR T-cell therapy.
Phase 2 · Italy · 14 sites
Registry update: 8 Oct 2026
NCT07453095
Recruiting
Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy
Phase 2 · Italy · 14 sites
Registry update: 25 Jun 2026
NCT07101328
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Phase 1 · Australia, Canada, Germany, Denmark, Spain, France, United Kingdom, Italy, Japan, South Korea, Poland, United States · 51 sites
Registry update: 4 Nov 2026
NCT07424833
Recruiting
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Phase 1 · China, United States · 6 sites
Registry update: 15 Oct 2026
NCT07377578
Recruiting
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 3 · China · 2 sites
Registry update: 6 Feb 2026
NCT07121946
Recruiting
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Phase 1 · United States · 6 sites
Registry update: 24 Jul 2026
NCT07261163
Recruiting
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
Phase 2 · China · 2 sites
Registry update: 13 May 2026

Ordered by registry start date. Freshness and sponsorship never change the order.